Mazor Advances Most Since October on FDA Approval of System

Dec. 5 (Bloomberg) -- Mazor Robotics Ltd. rose the most in almost two months after receiving approval from the U.S. Food and Drug Administration for the three dimensional use of its Renaissance system.

Shares in the developer of surgical robots surged 9.3 percent, the most since Oct. 16, to 4.246 shekels at the 4:30 p.m. close in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net